Actively Recruiting
Global Phase 23 Study of PF-08634404 Combined With Chemotherapy Versus Atezolizumab Plus Chemotherapy in Adults With Extensive-Stage Small Cell Lung Cancer
Led by Pfizer · Updated on 2026-10-08
550
Participants Needed
82
Research Sites
195 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new medicine called PF-08634404 to see how well it works when combined with chemotherapy in adults who have extensive-stage small cell lung cancer ES-SCLC, a fast-growing type of lung cancer that has spread widely. This study includes two parts the first part focuses on checking the safety and tolerance of the medicine with chemotherapy, while the second part compares this combination to an approved treatment using atezolizumab and chemotherapy. Participants will receive treatments through intravenous infusions in repeated cycles. Some participants may continue receiving PF-08634404 alone after the initial combined treatment phase. The study involves random assignment to either the PF-08634404 plus chemotherapy group or the atezolizumab plus chemotherapy group. During the study, participants will have regular assessments including scans to measure tumor response, physical exams, laboratory tests, and questionnaires to evaluate quality of life. The researchers will track outcomes such as tumor shrinkage, overall survival, adverse events, and treatment tolerance up to about two years after treatment completion. Safety and drug concentration in the blood will also be monitored closely throughout the trial.
CONDITIONS
Brief Title
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here